Lykos accepts FDA’s view that reviving rejected MDMA therapy’s fortunes requires fresh phase 3 trial

Lykos Therapeutics may have shed three-quarters of its staff in the wake of the FDA's rejection of its MDMA candidate for post-traumatic stress disorder, but the biotech’s new leadership believes the regulator may yet grant the company a path to approval.